Effect of tacrolimus and cyclosporine A on suppression of albumin secretion induced by inflammatory cytokines in cultured human hepatocytes

Inflammation Research

Volumn 55, Issue 5, 2006, Pages 216-220

  Li, Y ^a,b   Liu, F Y ^a   Liu, Z H ^b   Huang, Y F ^b   Li, L S ^b   Zhang, X ^b   Peng, Y M ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Albumin; Cyclosporine A (CSA); Hepatocyte tacrolimus (FK506); Inflammatory cytokine

Indexed keywords

ALBUMIN; CYCLOSPORIN A; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; LACTATE DEHYDROGENASE; TACROLIMUS;

ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; INFLAMMATION; LIVER CELL CULTURE; PROTEIN SECRETION; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; SPECTROPHOTOMETRY;

ALBUMINS; CELL LINE; CYCLOSPORINE; HEPATOCYTES; HUMANS; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKIN-6; L-LACTATE DEHYDROGENASE; TACROLIMUS;

EID: 33745852220     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-006-0074-0     Document Type: Article

References (35)

1. Don BR, Kaysen G. Serum albumin: relationship to Inflammation and nutrition. Semin Dial 2004; 17: 432-7.
2. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-86.
3. Brenner DA, Buck M, Feitelberg SP, Chojkier M. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 1990; 85 : 248-55.
4. Gabay C, Porter B, Guenette D, Billir B, Arend WP. Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1beta on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: differential effect on C-reactive protein production. Blood 1999; 93: 1299-307.
5. Li W, Li J, Gu J. Molecular mechanism and therapy of hypoalbuminemia in peritoneal infection. Zhonghua Wai Ke Za Zhi 1997; 35: 100-3.
6. Cross JT, Benton HP. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res 1999; 48: 255-61.
7. Rostoker G, Rymer JC, Bagnard G, Petit-Phar M, Griuncelli M, Pilatte Y. Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schonlein purpura nephritis, and a potential target of immunoglobulin therapy? Clin Exp Immunol 1998; 114: 468-76.
8. Mok CC, Tong KH, To CH, Siu YP, Au TC.Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study. Kidney Int 2005; 68 : 813-7.
9. Chen Q, Liu ZH, Hu WX, Yao XD, Chen HP, Chen X et al. A preliminary study of tacrolimus(FK506) treatment in patients with diffuse proliferative lupus nephritis a report of 9 case. Chinese Journal of nephrology,dialysis and transplantation 2002; 11: 301-7.
10. Chen Q, Liu ZH, Hu WX, Chen HP, Chen X, Li LS. A prospective study of tacrolimus(FK506) combined with low-dose prednisone in patients with membranous lupus nephropathy. Chinese Journal of nephrology,dialysis and transplantation 2004; 13: 101-6.
11. Tamura F, Masuhara A, Sakaida I, Fukumoto E, Nakamura T, Okita K.FK506 promotes liver regeneration by suppressing natural killer cell activity. J Gastroenterol Hepatol. 1998; 13(7): 703-8.
12. Kim YI, Kawano K, Iwao Y, Ono M, Goto S, Kobayashi M et al. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. Transplantation 1992; 53: 949-51.
13. Tanaka N, Yamamoto H, Tatemoto A, Urabe T, Orita K. Regulation of liver regeneration by interleukin-2 and its inhibitors: cyclosporine A and FK 506. Int J Immunopharmacol 1993; 15: 211-8.
14. Ebbs A, Pan F, Wynn C, Erickson L, Kobayashi M, Jiang H. Tacrolimus treats ongoing allograft rejection by inhibiting interleukin-10 mediated functional cytotoxic cell infiltration. Transplant Proc 2002; 34: 1378-81.
15. Jiang H, Wynn C, Pan F, Ebbs A, Erickson LM, Kobayashi M. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002; 73: 1808-17.
16. Sakuma S, Kato Y, Nishigaki F, Magari K, Miyata S, Ohkubo Y et al. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol 2001; 1: 749-57.
17. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80: S40-5.
18. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584-91.
19. Miyata S, Ohkubo Y, Mutoh S.A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm Res 2005; 54: 1-9.
20. Kaysen GA, Dubin JA, Muller HG, Rosales L, Levin NW, Mitch WE. HEMO Study Group NIDDK. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 2004; 65: 1408-15.
21. Odamaki M, Kato A, Kumagai H, Hishida A. Counter-regulatory effects of procalcitonin and indoxyl sulphate on net albumin secretion by cultured rat hepatocytes. Nephrol Dial Transplant 2004; 19: 797-804.
22. Danielski M, Ikizler TA, McMonagle E, Kane JC, Pupim L, Morrow J, et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 2003; 42: 286-94.
23. Louden JD, Bartlett K, Reaich D, Edson R, Alexander C, Goodship TH. Effects of feeding on albumin synthesis in hypoalbuminemic hemodialysis patients. Kidney Int 2002; 62: 266-71.
24. Giordano M, De Feo P, Lucidi P, DePascale E, Giordano G, Cirillo D et al. Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients. Kidney Int 2001; 60: 235-42.
25. Giordano M, De Feo P, Lucidi P, dePascale E, Giordano G, Infantone L et al. Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. J Am Soc Nephrol 2001; 12: 349-54.
26. Prinsen BH, Rabelink TJ, Beutler JJ, Kaysen GA, De Boer J, Boer WH et al. Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. Kidney Int 2003; 64: 1495-504.
27. Kaysen GA, Don BR. Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease. Kidney Int Suppl 2003; 84: S94-7.
28. Wustefeld T, Rakemann T, Kubicka S, Manns MP, Trautwein C. Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. Hepatology 2000; 32: 514-22.
29. Uchiyama T, Suzuki M, Unno M, Rikiyama T, Oikawa M, Matsuno S. Interleukin-10 induction after combined resection of liver and pancreas. Hepatogastroenterology 2001; 48: 1705-10.
30. Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales LM, Levin NW. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002; 61: 2240-9.
31. Singh A, Naidu PS, Patil CS, Kulkarni SK. Effect of FK506 (tacrolimus) in animal models of inflammation. Inflammopharmacology 2003; 11: 249-57.
32. Mori A, Suko M, Kaminuma O, Inoue S, Ohmura T, Hoshino A et al. IL-2-induced IL-5 synthesis, but not proliferation, of human CD4+ T cells is suppressed by FK506. J Immunol 1997; 158: 3659-65.
33. Rostaing L, Puyoo O, Tkaczuk J, Peres C, Rouzaud A, Cisterne JM et al. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients. Clin Transplant 1999; 13: 400-9.
34. Snyers L, De Wit L, Content J. Glucocorticoid up-regulation of high-affinity interleukin 6 receptors on human epithelial cells. Proc Natl Acad Sci USA 1990; 87: 2838-42.
35. Baumann H, Won KA, Jahreis GP. Human hepatocyte-stimulating factor-III and interleukin-6 are structurally and immunologically distinct but regulate the production of the same acute phase plasma proteins. J Biol Chem 1989; 264: 8046-51.